Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
NTLA 
Intellia Therapeutics Inc (NTLA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/27/2025: NTLA (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -62.3% | Avg. Invested days 19 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 03/27/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 860.23M USD | Price to earnings Ratio - | 1Y Target Price 43.92 |
Price to earnings Ratio - | 1Y Target Price 43.92 | ||
Volume (30-day avg) 3569179 | Beta 1.97 | 52 Weeks Range 8.11 - 28.18 | Updated Date 03/27/2025 |
52 Weeks Range 8.11 - 28.18 | Updated Date 03/27/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -5.25 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -1059.87% |
Management Effectiveness
Return on Assets (TTM) -26.8% | Return on Equity (TTM) -54.01% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 468913092 | Price to Sales(TTM) 14.86 |
Enterprise Value 468913092 | Price to Sales(TTM) 14.86 | ||
Enterprise Value to Revenue 8.1 | Enterprise Value to EBITDA -5.51 | Shares Outstanding 103517000 | Shares Floating 97913025 |
Shares Outstanding 103517000 | Shares Floating 97913025 | ||
Percent Insiders 5.05 | Percent Institutions 91.72 |
Analyst Ratings
Rating 4.39 | Target Price 57.76 | Buy 5 | Strong Buy 17 |
Buy 5 | Strong Buy 17 | ||
Hold 6 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Intellia Therapeutics Inc
Company Overview
History and Background
Intellia Therapeutics Inc. was founded in 2014. It is a biotechnology company focused on developing curative therapeutics using CRISPR/Cas9 technology.
Core Business Areas
- Genome Editing Therapies: Development of in vivo and ex vivo CRISPR-based therapies for genetic diseases. In vivo therapies involve delivering the CRISPR components directly into the patient's body, while ex vivo therapies involve modifying cells outside the body and then transplanting them back into the patient.
- Platform Technology: Advancing and refining its CRISPR/Cas9 technology platform to improve delivery efficiency, specificity, and efficacy.
Leadership and Structure
The leadership team includes John Leonard, M.D. (President and CEO), and other executives in research and development, finance, and operations. The organizational structure is typical of a biotechnology company, with research, development, clinical, and administrative departments.
Top Products and Market Share
Key Offerings
- NTLA-2001 (Transthyretin Amyloidosis): An in vivo CRISPR-based therapy for transthyretin (ATTR) amyloidosis. Phase 1 clinical trials have shown promising results in reducing TTR protein levels. Competitors include Alnylam Pharmaceuticals (ONPATTRO, AMVUTTRA) and Ionis Pharmaceuticals (Wainua). Market share is currently developing based on the treatment landscape with these competitors.
- NTLA-2002 (Hereditary Angioedema): An in vivo CRISPR-based therapy for hereditary angioedema (HAE). Phase 1/2 study underway with positive initial results. Competitors include BioCryst Pharmaceuticals (ORLADEYO) and Takeda Pharmaceuticals (TAKHZYRO). Market share is currently developing based on the treatment landscape with these competitors.
Market Dynamics
Industry Overview
The gene editing therapy market is rapidly growing, driven by advancements in CRISPR technology and increasing demand for treatments for genetic diseases. Key players include Intellia, CRISPR Therapeutics, Editas Medicine, and Beam Therapeutics.
Positioning
Intellia is a leading company in the CRISPR gene editing space, with a focus on in vivo therapies. Its competitive advantage lies in its proprietary delivery technology and early clinical data.
Total Addressable Market (TAM)
The estimated global gene editing market is expected to reach billions of dollars in the next decade. Intellia is well-positioned to capture a significant share of this market, especially in areas like ATTR amyloidosis and HAE. Specific TAM figures depend on disease prevalence and treatment costs.
Upturn SWOT Analysis
Strengths
- Leading CRISPR technology platform
- Strong intellectual property portfolio
- Promising early clinical data
- Experienced management team
- Strategic partnerships (e.g., with Regeneron)
Weaknesses
- High research and development costs
- Reliance on clinical trial success
- Potential for off-target effects with CRISPR
- Competition from other gene editing companies
- Regulatory uncertainties
Opportunities
- Expanding pipeline of CRISPR therapies
- Partnerships with pharmaceutical companies
- Advancements in delivery technology
- Expanding into new therapeutic areas
- Regulatory approvals for CRISPR therapies
Threats
- Clinical trial failures
- Competition from other gene editing technologies
- Adverse events in clinical trials
- Changes in regulatory landscape
- Patent disputes
Competitors and Market Share
Key Competitors
- CRSP
- EDIT
- BEAM
Competitive Landscape
Intellia competes with other gene editing companies based on technology, pipeline, and partnerships. Intellia's advantage lies in its in vivo approach. They are all generally working to treat similar diseases and using CRISPR-based approaches.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Intellia's historical growth has been characterized by advancements in its CRISPR platform, expansion of its pipeline, and strategic collaborations.
Future Projections: Future growth is expected to be driven by clinical trial successes, regulatory approvals, and commercialization of its therapies. Analyst estimates vary depending on the success of the pipeline. Revenue will be driven by potential royalty of any developed product.
Recent Initiatives: Recent initiatives include advancing clinical trials for NTLA-2001 and NTLA-2002, expanding its CRISPR platform, and forming new partnerships.
Summary
Intellia is a key player in the CRISPR gene editing space with promising in vivo therapies. Its success hinges on clinical trial outcomes and navigating regulatory hurdles. Partnerships and continued platform innovation are crucial for future growth. It faces strong competition and the inherent risks of biotechnology development. They must execute clinically to capitalize on any market share.
Similar Companies
- CRSP
- EDIT
- BEAM
- REGN
Sources and Disclaimers
Data Sources:
- Company Filings
- Analyst Reports
- Industry News
- Clinicaltrials.gov
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be based on individual research and consultation with a qualified financial advisor. Market share percentages are estimates and may not reflect precise figures.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Intellia Therapeutics Inc
Exchange NASDAQ | Headquaters Cambridge, MA, United States | ||
IPO Launch date 2016-05-06 | President, CEO & Director Dr. John M. Leonard M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 403 | Website https://www.intelliatx.com |
Full time employees 403 | Website https://www.intelliatx.com | ||
Intellia Therapeutics, Inc., a clinical-stage gene editing company, focuses on the development of curative genome editing treatments. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 that is in Phase 1/2 study for the treatment of hereditary angioedema. It also focusses on the research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. The company has license and collaboration agreement with AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of various of B cell-mediated autoimmune diseases; ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer; and ReCode Therapeutics, Inc. to develop novel genomic medicines for the treatment of cystic fibrosis. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.